Full Text Content : List of Headings Add Content

Article Name - Hypocalcaemia Induced by Denosumab Therapy: A Cautionary Tale in Osteoporosis Management

Heading Content Date Edit Delete
  • Introduction Denosumab is a fully human monoclonal antibody widely used in the treatment of osteoporosis due to its potent antiresorptive properties. By inhibiting RANKL (Receptor Activator of Nuclear Factor-κB ... 2025-10-07
  • Description Hypocalcaemia is a known but often underrecognized complication of denosumab therapy, particularly after the initial dose. Unlike bisphosphonates, which gradually inhibit bone resorption, denosumab ex ... 2025-10-07
  • Conclusion Denosumab is a highly effective agent for osteoporosis, but its use is not without risk. Hypocalcaemia, though rare, can be serious and even fatal if not recognized early. This case underscores the im ... 2025-10-07
  • Acknowledgement None. ... 2025-10-07
  • Conflict of Interest None. ... 2025-10-07
  • References Kanis, John A., D. Hans, Cyrus Cooper and Sanford Baim, et al. "Interpretation and use of FRAX in clinical practice." Osteoporos Int 22 (2011): 2395-2411. Google Scholar    &n ... 2025-10-07